ライフサイエンスコーパス: pancreatectomy

1 ssed (eg, median pancreatectomy and extended pancreatectomy).

2 7.3% (distal pancreatectomy) to 22.9% (total pancreatectomy).

3 ing either pancreaticoduodenectomy or distal pancreatectomy.

4 antly affect QoL in emergency laparotomy and pancreatectomy.

5 hat is unresponsive to diazoxide is subtotal pancreatectomy.

6 .14) for gastrectomy to 1.45 (1.21-1.73) for pancreatectomy.

7 y, and recovery as compared with open distal pancreatectomy.

8 ly associated with poorer survival following pancreatectomy.

9 partial pancreatic duct ligation or partial pancreatectomy.

10 y broaden indications for minimally invasive pancreatectomy.

11 odenectomy and 257 +/- 93 minutes for distal pancreatectomy.

12 as associated with higher risk for allograft pancreatectomy.

13 nding the indications for minimally invasive pancreatectomy.

14 potential cause of recurrence after partial pancreatectomy.

15 ncreatic fistula in patients undergoing left pancreatectomy.

16 is the most frequent complication after left pancreatectomy.

17 deemed unsalvageable and required allograft pancreatectomy.

18 opic or surgical means, and partial or total pancreatectomy.

19 ndividuals may be managed medically, without pancreatectomy.

20 pancreas sparing operation such as a central pancreatectomy.

21 on such as pancreaticoduodenectomy or distal pancreatectomy.

22 on that occurs after pancreatitis or partial pancreatectomy.

23 dical therapy, without the need for surgical pancreatectomy.

24 lable medical therapy and require palliative pancreatectomy.

25 creases of children with KATPHI who required pancreatectomy.

26 generation of new acinar cells after partial pancreatectomy.

27 to 9.2 (95% CI, 6.7 to 10.4 lives saved) for pancreatectomy.

28 cystectomy to 4.9 (95% CI, 2.4 to 10.1) for pancreatectomy.

29 the setting of insulin resistance, or after pancreatectomy.

30 in each patient, were used to guide partial pancreatectomy.

31 l pancreatectomy, and 56 (89%) had a partial pancreatectomy.

32 y play a role in diabetes secondary to total pancreatectomy.

33 2 patients (68% [95% CI, 49%-88%]) underwent pancreatectomy.

34 bine (825 mg/m2 orally twice daily) prior to pancreatectomy.

35 avin-1 may improve the long-term efficacy of pancreatectomy.

36 fluid administration on morbidity following pancreatectomy.

37 8 (71.2%), hip replacement; and 2276 (1.8%), pancreatectomy.

38 ne cells after beta-cell ablation or partial pancreatectomy.

39 d Whipple procedure and 7 patients had total pancreatectomy.

40 ul islet isolation after near-total or total pancreatectomy.

41 7.5% after hip replacement, and 16.3% after pancreatectomy.

42 elated deaths occurred within 365 days after pancreatectomy.

43 of patients required early readmission after pancreatectomy.

44 a near-total pancreatectomy, and one partial pancreatectomy.

45 pair, colectomy, total hip arthroplasty, and pancreatectomy.

46 2 with distal pancreatectomy, 2 with central pancreatectomy, 1 with total pancreatectomy) for failure

47 y (132), distal pancreatectomy (83), central pancreatectomy (13), pancreatic enucleation (10), total

48 after AAA repair (8.8% vs 9.3%; P = .55) and pancreatectomy (17.5% vs 15.9%; P = .40).

49 oplasm, recurrence was similar after partial pancreatectomy (18/27; 67%) and total pancreatectomy (8/

50 olectomy: 25.8%; hip replacement: 32.5%; and pancreatectomy: 19.7%) compared with the index hospitali

51 1,191 colectomies, 2,670 cystectomies, 1,514 pancreatectomies, 2,607 proctectomies, 12,228 prostatect

52 with pancreaticoduodenectomy, 2 with distal pancreatectomy, 2 with central pancreatectomy, 1 with to

53 With low-volume standards (1/year for pancreatectomy; 2/year for esophagectomy), approximately

54 ived closer to a higher-volume hospital (25% pancreatectomy; 26% esophagectomy).

55 5-year survival were good for standard total pancreatectomies (28.6 months and 24.3%, respectively) a

56 creatic gastrinoma resected by means of left pancreatectomy 31 years before, hyperparathyroidism trea

57 amatic increases seen for gastrectomy (54%), pancreatectomy (31%), and thyroidectomy (23%).

58 Distal pancreatectomy (40%), enucleation (34%), and pancreatico

59 omy (13), pancreatic enucleation (10), total pancreatectomy (5), Appleby resection (4), and Frey proc

60 arge portion of the decline in mortality for pancreatectomy (67% of the decline), cystectomy (37%), a

61 erative morbidity was higher following total pancreatectomy (69.0% vs. 38.6% for pancreaticoduodenect

62 o 0.95) and 80 patients who underwent distal pancreatectomy (7% vs. 23%; relative risk, 0.32; 95% CI,

63 For distal pancreatectomies (7085 patients; 6.2% mortality), there

64 A similar proportion of total pancreatectomy (74.7%) and pancreaticoduodenectomy (78.3

65 travel less than 30 additional minutes (74% pancreatectomy; 76% esophagectomy).

66 artial pancreatectomy (18/27; 67%) and total pancreatectomy (8/13; 62%) and occurred within 3 years o

67 lyzed; pancreaticoduodenectomy (132), distal pancreatectomy (83), central pancreatectomy (13), pancre

68 redictor of mortality for the performance of pancreatectomy, AAA repair, esophagectomy, or CABG.

69 ver 60 years had higher mortality rates with pancreatectomy (adjusted odds ratio [OR], 1.67; 95% conf

70 inical dilemma of balancing the morbidity of pancreatectomy against the risk of malignant transformat

71 d to improve glycemic control after extended pancreatectomy, almost exclusively in patients with chro

72 eneic islet transplantation as well as total pancreatectomy alone (nontransplanted group).

73 Partial pancreatectomy also caused a approximately 40% decrease

74 chronic hyperglycemia following 90% partial pancreatectomy also led to reduced Uch-L1 expression.

75 hepatectomy performing 11% (n = 291) of the pancreatectomies and 12% (n = 474) of the hepatectomies

76 level, this projected to 42,320 open distal pancreatectomies and 1908 MIDPs.

77 In the study period, there were 2592 pancreatectomies and 3734 hepatectomies performed at 110

78 s reflect the invasiveness of extended total pancreatectomies and the underlying advanced malignant d

79 ition, there were 10 high-volume centers for pancreatectomy and 12 centers for hepatectomy performing

80 ancreatitis recipients 1-8 years after total pancreatectomy and autoislet transplantation.

81 erwent primary open DP (excluding completion pancreatectomy and debridement) between January 1, 1984

82 mortality rates were significantly lower for pancreatectomy and esophagectomy at Specialized Centers.

83 been described and are discussed (eg, median pancreatectomy and extended pancreatectomy).

84 atify superficial and organ-space SSIs after pancreatectomy and investigate their modifiable risk fac

85 mplications, and long-term outcomes of total pancreatectomy and islet autotransplantation (TP-IAT) in

86 ze factors predicting outcomes after a total pancreatectomy and islet autotransplantation (TP-IAT).

87 Total pancreatectomy and islet autotransplantation is an effec

88 Total pancreatectomy and islet autotransplantation provides su

89 Total pancreatectomy and islet cell autotransplantation (TPIAT

90 surgical procedures such as combined distal pancreatectomy and left nephrectomy can be safely perfor

91 t the first reported combined robotic distal pancreatectomy and left nephrectomy from a live donor.

92 Total pancreatectomy and marginal mass islet autotransplantati

93 Total pancreatectomy and pancreaticoduodenectomy patients had

94 ticoduodenectomy, and 1 patient had a distal pancreatectomy and splenectomy.

95 studies to pancreatic injury models (partial pancreatectomy and streptozotocin administration).

96 Overall, 22,366 patients underwent a pancreatectomy and the mortality was 8.1%.

97 uding 27 with localized tumors (11 underwent pancreatectomy, and 16 had localized nonresectable tumor

98 derwent surgery, 96.0% (2630/2736) underwent pancreatectomy, and 4.0% (458/2736) had unresectable tum

99 was unresectable, 6 (10%) underwent a total pancreatectomy, and 56 (89%) had a partial pancreatectom

100 exenatide, streptozotocin injection, partial pancreatectomy, and high fat diet.

101 DZX), and nine of whom required a near-total pancreatectomy, and one partial pancreatectomy.

102 s, including pancreaticoduodenectomy, distal pancreatectomy, and total pancreatectomy, remain the onl

103 antation; (4) improving outcomes after total pancreatectomy; and (5) registry considerations for TPIA

104 Pancreaticoduodenectomy and distal pancreatectomy are associated with significant periopera

105 or left pancreatectomy, as indicated); total pancreatectomy as an alternative to high-risk anastomosi

106 n properly weigh the risks and advantages of pancreatectomy as treatment of PDA.

107 Central pancreatectomy, as an alternative to standard resection

108 tic fistula (treated with completion or left pancreatectomy, as indicated); total pancreatectomy as a

109 ve analysis of all minimally invasive distal pancreatectomies at University of Pittsburgh Medical Cen

110 All patients undergoing left pancreatectomy at a large tertiary hospital were eligibl

111 to statewide data of patients who underwent pancreatectomy at a tertiary care referral center betwee

112 n was determined in 173 patients after total pancreatectomy at our center.

113 Donor animals underwent partial pancreatectomy, autologous islet preparation, and inject

114 tion (IAT) in patients undergoing completion pancreatectomy because of sepsis or bleeding after pancr

115 P < 0.05), insulin sensitivity after partial pancreatectomy being related to insulin pulse amplitude

116 identify all adult patients who had elective pancreatectomies between 2007 and 2012.

117 a who received preoperative therapy prior to pancreatectomy between 1990 and 2015.

118 eview of 721 patients who underwent a distal pancreatectomy between February 1986 and February 2009.

119 After partial pancreatectomy both basal and glucose-stimulated insulin

120 Six hundred and ninety-three left pancreatectomy cases (439 OLP, 254 LLP) were analyzed.

121 y bypass surgery, oesophagectomy, colectomy, pancreatectomy, cholecystectomy, ventral hernia repair,

122 < .001) and operative characteristics (total pancreatectomy: coefficient, 12 742.31; 95% CI, 10 063.6

123 omes and hospital charge measures for distal pancreatectomy, comparing the surgical approaches and ad

124 BD donors (cases) and subjects who underwent pancreatectomy (controls).

125 geons' National Surgical Quality Improvement Pancreatectomy Demonstration Project at 37 high-volume c

126 lications and pancreatic fistulae after left pancreatectomy differ when open versus laparoscopic tech

127 elopment of PL in patients undergoing distal pancreatectomy (DP) at a single high-volume institution.

128 te of new-onset diabetes (NODM) after distal pancreatectomy (DP) is not known.

129 l, the early and long-term outcome of distal pancreatectomy (DP) performed by laparoscopy (LapDP) or

130 study was to test the hypothesis that distal pancreatectomy (DP) without intraperitoneal drainage doe

131 ring on pancreatic fistula rate after distal pancreatectomy (DP).

132 y (PD, n = 218), central (n = 16), or distal pancreatectomy (DP, n = 96).

133 Among all 623 patients who underwent pancreatectomy during the study period, 134 (21.5%) were

134 dergoing 6 major operations in 2005 to 2006: pancreatectomy, esophagectomy, abdominal aortic aneurysm

135 tured abdominal aortic aneurysms, colectomy, pancreatectomy, esophagectomy, and repair of hip fractur

136 After partial pancreatectomy, Feridex-labeled islets were prepared and

137 baboons (Papio hamadryas) underwent partial pancreatectomy, followed by continuous infusion of EXE o

138 data on esophagectomies, gastrectomies, and pancreatectomies for cancer from the NHS Hospital Episod

139 A total of 434 consecutive total pancreatectomies for primary pancreatic or periampullary

140 rgoing laparoscopic spleen-preserving distal pancreatectomy for benign or low-grade malignant tumors

141 erwent laparoscopic spleen-preserving distal pancreatectomy for benign or lowgrade malignant tumors i

142 s during pancreaticoduodenectomy; and distal pancreatectomy for benign/borderline neoplasm of pancrea

143 st, islet autografts, infused at the time of pancreatectomy for chronic pancreatitis, are not subject

144 s to define factors affecting outcomes after pancreatectomy for neoplasm.

145 operative mortality for patients undergoing pancreatectomy for neoplastic disease from 1998 to 2003.

146 ients who underwent preoperative therapy and pancreatectomy for pancreatic ductal adenocarcinoma.

147 in two recipients of islet autografts after pancreatectomy for pancreatitis versus five control subj

148 o identify factors predicting survival after pancreatectomy for PNETs and to establish a postresectio

149 Total pancreatectomy for presumed painful chronic pancreatitis

150 a in patients undergoing near-total or total pancreatectomy for severe chronic pancreatitis.

151 t worse survival than patients who underwent pancreatectomy for Stage I disease (P < 0.0001).

152 2 with central pancreatectomy, 1 with total pancreatectomy) for failure to progress (14) and bleedin

153 n margins) collected prospectively during 32 pancreatectomies from February 27, 2013, to January 16,

154 s, among patients undergoing elective distal pancreatectomy from 1998 to 2009 in the Nationwide Inpat

155 Tissue was isolated during pancreatectomy from eight patients with CHI and from adu

156 e: lung resection, esophagectomy, colectomy, pancreatectomy, gastrectomy, abdominal aortic aneurysm r

157 Partial pancreatectomy greatly stimulated beta-cell proliferatio

158 he Whipple procedure group than in the total pancreatectomy group (median survival 19 months vs 4 mon

159 ith very high-volume standards (>16/year for pancreatectomy; >19/year for esophagectomy), approximate

160 Four of six patients with total pancreatectomy had islet yields exceeding 5000 islet equ

161 The role of total pancreatectomy has historically been limited due to conc

162 my, cholecystectomy, splenectomy, and distal pancreatectomy have been performed successfully via tran

163 r outcomes of MIDP compared with open distal pancreatectomy have been reported.

164 nificant difference in the incidence of post-pancreatectomy hemorrhage, delayed gastric emptying, inf

165 They also can be cured by selective partial pancreatectomy; however, unlike those with a K(ATP) foca

166 tion of diabetes in patients requiring total pancreatectomy if the pancreas is not extensively fibrot

167 Standard total pancreatectomy, if needed, is associated with good long-

168 atients, total pancreatectomy in 15%, distal pancreatectomy in 12%, and central pancreatic resection

169 tomy was performed in 71% of patients, total pancreatectomy in 15%, distal pancreatectomy in 12%, and

170 ver, no studies assessing the impact of hemi-pancreatectomy in humans on islet alpha-cell responses t

171 f new beta-cells during adult life and after pancreatectomy in mice.

172 nced hands, the rates of complications after pancreatectomy in patients 80 years or older compared to

173 formed as an alternative approach for distal pancreatectomy in selected patients.

174 Three patients underwent noncurative distal pancreatectomy in the early period.

175 udy to characterize the striking underuse of pancreatectomy in the United States.

176 unders using instrumental variable analysis, pancreatectomy is associated with a statistically signif

177 Central pancreatectomy is associated with an excellent pancreati

178 Readmission after pancreatectomy is common, but few data compare patterns

179 Distal pancreatectomy is the standard procedure for removal of

180 After total pancreatectomy, islets were isolated by using a two-step

181 Laparoscopic distal pancreatectomy (LDP) reduces postoperative morbidity, ho

182 Laparoscopic left pancreatectomy (LLP) is associated with favorable outcom

183 e of ages with a variety of stimuli: partial pancreatectomy, low-dose administration of the beta-cell

184 d age in mice, whether stimulated by partial pancreatectomy, low-dose streptozotocin, or exendin-4.

185 Total pancreatectomy may be required in locally advanced or ce

186 oplasms, 5 of 60 (8%) recurred after partial pancreatectomy (median follow-up, 37 months); none recur

187 ection factors for minimally invasive distal pancreatectomy (MIDP) and identify actual risk factors f

188 of open (ODP) and minimally invasive distal pancreatectomy (MIDP) are equivalent for benign lesions.

189 Interest in minimally invasive distal pancreatectomy (MIDP) has grown in recent years, but cur

190 With the pancreatectomy model, expression of polyubiquitin-B and

191 ses Morbidity" to 0% for "Procedure-Targeted Pancreatectomy Mortality." For Essentials models, averag

192 1970 and 2007, patients who underwent total pancreatectomy (n = 100) or pancreaticoduodenectomy (n =

193 nts undergoing hepatectomy (n = 2811) and/or pancreatectomy (n = 1092) from January 1997 to December

194 t was relevant in certain subgroups (upfront pancreatectomy (n = 117; P = 0.049); without VR or NAT (

195 ow-up, 37 months); none recurred after total pancreatectomy (n = 13; median follow-up, 32 months).

196 ncreatoduodenectomy (n = 514; 88.2%), distal pancreatectomy (n = 62; 10.6%), or total pancreatectomy

197 tal pancreatectomy (n = 62; 10.6%), or total pancreatectomy (n = 7; 1.2%).

198 -6 months, underwent partial (n=4), or total pancreatectomy (n=11), and transplantation of autologous

199 ), Whipple or Beger procedure (n=14), distal pancreatectomy (n=8), or lateral pancreaticojejunostomy

200 75%)], tail resections [n = 16 (15%)], total pancreatectomies [n = 5 (5%)], and segment resections [n

201 he SMA-margin in specific subgroups (upfront pancreatectomy, N0 patients without NAT, N+ patients wit

202 d further intervention, including completion pancreatectomy, neurolysis, and sphincteroplasty.

203 ucose and arginine are diminished after hemi-pancreatectomy, no deficiency in glucagon responses were

204 r adverse outcomes compared with open distal pancreatectomy (ODP).

205 h favorable outcomes compared with open left pancreatectomy (OLP).

206 to undergo surgery and assess the impact of pancreatectomy on survival.

207 However, total pancreatectomy operative mortality decreased over time (

208 All patients who were subjected to pancreatectomy or hepatectomy for cancer in the years 19

209 let yield compared with those who had distal pancreatectomy or lateral pancreaticojejunostomy.

210 rowth in response to nutrients and following pancreatectomy or pancreatitis.

211 rgical beta-cell replication models (partial pancreatectomy or partial duct ligation), representing t

212 rgest for patients who were readmitted after pancreatectomy (OR 0.56, 95% CI 0.45-0.69) and aortobife

213 eplacement (OR, 0.97; 95% CI, 0.91-1.03), or pancreatectomy (OR, 1.02; 95% CI, 0.76-1.36).

214 isease (OR, 2.28; 95% CI, 1.23-4.24), distal pancreatectomy (OR, 1.77; 95% CI, 1.11-2.84), and postop

215 , gastrectomy, hysterectomy, lung resection, pancreatectomy, or prostatectomy were identified retrosp

216 mplexities of chronic pancreatitis and total pancreatectomy outcomes and postsurgical diabetes outcom

217 or patients resected at high-volume centers (pancreatectomy: P = 0.001; hepatectomy: P = 0.02).

218 tive abdominal aortic aneurysm repair (AAA), pancreatectomy (PAN), and esophagectomy (ESO) as primary

219 tive abdominal aortic aneurysm repair (AAA), pancreatectomy (PAN), and esophagectomy (ESO).

220 f 596,222 patients undergoing esophagectomy, pancreatectomy, partial or total gastrectomy, colectomy,

221 Total pancreatectomy patients had larger median tumor size (4

222 Total pancreatectomy patients had more lymph nodes harvested (

223 For pancreatectomy patients, mortality increases with increa

224 from 1 to 14 gastrectomies, and from 2 to 31 pancreatectomies per surgeon per year.

225 cilities performing </=25, 26 to 65, and >65 pancreatectomies per year was 456, 20, and 9, respective

226 ty), there were 2 cut-offs (13 and 25 distal pancreatectomies per year), but neither was an independe

227 The proportion of distal pancreatectomies performed via minimally invasive approa

228 Total pancreatectomy perioperative mortality dramatically decr

229 s (prostatectomy, cystectomy, esophagectomy, pancreatectomy, pneumonectomy, and liver resection) betw

230 undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs place

231 In the partial pancreatectomy (Ppx) model, exogenous Ex-4 promotes isle

232 e low-dose streptozotocin (MLDS) and partial pancreatectomy (Ppx).

233 or neogenesis in the adult after 60% partial pancreatectomy (PPx).

234 ons of pancreas transplantation: 70% partial pancreatectomy (PPX, n = 4), partial pancreatectomy with

235 my, aortic valve replacement, esophagectomy, pancreatectomy, pulmonary resection, hepatectomy, colect

236 ing on pancreatic regeneration after partial pancreatectomy (Px) and (2) define the involvement of th

237 Of these, 50 underwent allograft pancreatectomy (Px) and 196 did not (no-Px).

238 e analyzed for 15 days following 60% partial pancreatectomy (Px).

239 We hypothesized that robot-assisted distal pancreatectomy (RADP) was superior to LDP as a result of

240 safety of the preoperative regimen, and the pancreatectomy rate.

241 Pancreatectomy rates were examined within Health Service

242 ice (PANC PPARgamma(-/-)), normoglycemic 60% pancreatectomy rats (Px), normoglycemic and hyperglycemi

243 inforcement of stapled closure during distal pancreatectomy reduces the rate of fistula formation.

244 odenectomy, distal pancreatectomy, and total pancreatectomy, remain the only potentially curative int

245 36 patients who failed to respond to distal pancreatectomy required further intervention, including

246 to restoration of normoglycemia, near-total pancreatectomy resulted in hyperglycemia, suggesting tha

247 Partial pancreatectomy resulted in IFG and IGT.

248 Analysis of readmissions after pancreatectomy reveals it to be a poor quality of care m

249 There is agreement that pancreatectomies should be centralized.

250 Total pancreatectomy should be performed when oncologically ap

251 Only pancreatectomy showed a notable decrease in strength of

252 N-2, and 11 PanIN-3) that were selected from pancreatectomy specimens for either adenocarcinoma or ch

253 We obtained pancreatectomy specimens from 20 patients with chronic p

254 precursor lesions, PanINs, from prophylactic pancreatectomy specimens of patients from four different

255 Measure the caseload of pancreatectomies that influences their short-term outcom

256 All patients underwent curative pancreatectomy; those with pancreatic cancer were chemot

257 AT during nonemergency preemptive completion pancreatectomy through the pancreaticoduodenectomy.

258 ctal procedures, esophagectomy, gastrectomy, pancreatectomy, thyroidectomy, coronary artery bypass gr

259 unresponsive to medical therapy will require pancreatectomy to control the hypoglycemia.

260 on: miniature swine underwent either partial pancreatectomy to isolate autologous islets or total pan

261 ectomy to isolate autologous islets or total pancreatectomy to isolate minor antigen-mismatched islet

262 Donors undergoing hemi-pancreatectomy to provide a pancreas segment for transpl

263 ted with mortality ranging from 7.3% (distal pancreatectomy) to 22.9% (total pancreatectomy).

264 Total pancreatectomy (TP) removes the source of the pain, wher

265 One week after a pancreatectomy, TTP/HUS developed that resolved with clo

266 tapled left pancreatectomy with stapled left pancreatectomy using mesh reinforcement of the staple li

267 Long-term survival following total pancreatectomy versus pancreaticoduodenectomy was equiva

268 sm, we performed a approximately 50% partial pancreatectomy versus sham surgery in 14 dogs.

269 e resection margins (22.2% vs. 43.7%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively

270 perineural invasion (90.7% vs. 91.8%) (total pancreatectomy vs. pancreaticoduodenectomy, respectively

271 tes of resection in their geographic region, pancreatectomy was associated with a statistically signi

272 Total pancreatectomy was associated with higher 30-day mortali

273 The annual-caseload of pancreatectomy was calculated for each hospital facility

274 Total pancreatectomy was increasingly used over time (1970-198

275 Pancreatectomy was performed in 4322 of 8323 patients ev

276 Minimally invasive distal pancreatectomy was performed increasingly in later study

277 phagectomies, 12,622 gastrectomies, and 9116 pancreatectomies were examined.

278 etherlands (2005 to 2013) only 10% of distal pancreatectomies were in a minimally invasive fashion an

279 A total of 8957 distal pancreatectomies were included in this analysis, of whic

280 gectomies, 20,362 lung resections, and 2,844 pancreatectomies were included.

281 In addition, a greater proportion of pancreatectomies were performed at high-volume centers i

282 Eleven of these pancreatectomies were performed at the time of repeat tr

283 Extended total pancreatectomies were performed in 54% of cases, with ar

284 Central pancreatectomies were performed mainly for neuroendocrin

285 patients who developed diabetes after total pancreatectomy were candidates for the autologous transp

286 patients and 20 control patients undergoing pancreatectomy were studied.

287 but, with the exception of surgical partial pancreatectomy, were not extensively beta-cells.

288 oach has been the move to minimally invasive pancreatectomy, which continues to gain broader acceptan

289 incidence and indications for late allograft pancreatectomy while on continued immunosuppression for

290 sive pancreatic adenocarcinoma who underwent pancreatectomy with curative intent.

291 Total pancreatectomy with islet autotransplantation (TP-IAT) i

292 on research gaps and opportunities in total pancreatectomy with islet autotransplantation (TPIAT) fo

293 ain but has not been widely applied to total pancreatectomy with islet autotransplantation (TPIAT).

294 100 consecutive patients undergoing central pancreatectomy with pancreaticogastrostomy from January

295 al venous diversion (SC, n = 4), and partial pancreatectomy with remnant autotransplantation (PAT, n

296 The patient underwent total pancreatectomy with splenectomy.

297 partial pancreatectomy (PPX, n = 4), partial pancreatectomy with splenocaval venous diversion (SC, n

298 ized controlled trial comparing stapled left pancreatectomy with stapled left pancreatectomy using me

299 n = 4) or fully-mismatched (n = 2) IKs after pancreatectomy, with a 12-day course of cyclosporine A (

300 onal case of esophagectomy, gastrectomy, and pancreatectomy would reduce 30-day mortality odds by 3.4